The ajmaline challenge in Brugada syndrome: Diagnostic impact, safety, and recommended protocol

European Heart Journal

Volumn 24, Issue 12, 2003, Pages 1104-1112

  Rolf, Sascha ^a   Bruns, Hans Jürgen ^a   Wichter, Thomas ^a   Kirchhof, Paulus ^a   Ribbing, Michael ^a   Wasmer, Kristina ^a   Paul, Matthias ^a   Breithardt, Günter ^a   Haverkamp, Wilhelm ^a   Eckardt, Lars ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Ajmatine chattenge; Brugada syndrome; Proarrhythmia; Safety; Test protocol

Indexed keywords

AJMALINE; ANTIARRHYTHMIC AGENT; DISOPYRAMIDE; FLECAINIDE; PROCAINAMIDE; PROPAFENONE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BRUGADA SYNDROME; CLINICAL PROTOCOL; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG SAFETY; ECG ABNORMALITY; ELECTROCARDIOGRAM; FAMILY HISTORY; FEMALE; FRACTIONATION; HEADACHE; HEART ARRHYTHMIA; HEART PROARRHYTHMIA; HEART SINOATRIAL BLOCK; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROVOCATION TEST; QRS COMPLEX; RISK ASSESSMENT; SCHOOL CHILD; SIDE EFFECT; ST SEGMENT ELEVATION; STANDARD; SUDDEN DEATH; SYNCOPE; TECHNIQUE; TORSADE DES POINTES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AJMALINE; ANTI-ARRHYTHMIA AGENTS; BUNDLE-BRANCH BLOCK; CHILD; CLINICAL PROTOCOLS; DEATH, SUDDEN, CARDIAC; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; SYNCOPE; SYNDROME;

EID: 0037494946     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(03)00195-7     Document Type: Article

References (26)

1. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992;20(6):1391-6.
2. Wilde AA, Antzelevitch C, Borggrefe M et al. Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J 2002;23(21):1648-54.
3. Chen Q, Kirsch GE, Zhang D et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998;392(6673):293-6.
4. Brugada J, Brugada R, Antzelevitch C et al. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation 2002;105(1):73-8.
5. Priori SG, Napolitano C, Gasparini M et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 2002;105(11):1342-7.
6. Brugada J, Brugada P. Further characterization of the syndrome of right bundle branch block, ST segment elevation, and sudden cardiac death. J Cardiovasc Electrophysiol 1997;8(3):325-31.
7. Brugada R, Brugada J, Antzelevitch C et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000;101(5):510-5.
8. Miyazaki T, Mitamura H, Miyoshi S et al. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996;27(5):1061-70.
9. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999;100(15):1660-6.
10. Wichter T, Matheja P, Eckardt L et al. Cardiac autonomic dysfunction in Brugada syndrome. Circulation 2002;105(6):702-6.
11. Shimizu W, Antzelevitch C, Suyama K et al. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2000;11(12):1320-9.
12. Eckardt L, Kirchhof P, Johna R et al. Transient local changes in right ventricular monophasic action potentials due to ajmaline in a patient with Brugada Syndrome. J Cardiovasc Electrophysiol 1999;10(7):1010-5.
13. Brugada P, Brugada J, Brugada R. Localized' right ventricular morphological abnormalities in patients with the Brugada syndrome: what is their significance? Eur Heart J 2001;22(12):982-4.
14. Padrini R, Piovan D, Javarnaro A et al. Pharmacokinetics and electrophysiological effects of intravenous ajmaline. Clin Pharmacokinet 1993;25(5):408-14.
15. Haverkamp W, Monnig G, Kirchhof P et al. Torsade de pointes induced by ajmaline. Z Kardiol 2001;90(8):586-90.
16. Pinar BE, Garcia-Alberola A, Martinez SJ et al. Spontaneous sustained monomorphic ventricular tachycardia after administration of ajmaline in a patient with Brugada syndrome. Pacing Clin Electrophysiol 2000;23(3):407-9.
17. Eckardt L, Bruns HJ, Paul M et al. Body surface area of ST elevation and the presence of late potentials correlate to the inducibility of ventricular tachyarrhythmias in Brugada syndrome. J Cardiovasc Electrophysiol 2002;13(8):742-9.
18. Wellens HJ, Bar FW, Vanagt EJ. Death after ajmaline administration. Am J Cardiol 1980;45(4):905.
19. Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med 1994;331(12):785-91.
20. Antzelevitch C, Brugada P, Brugada J et al. The Brugada Syndrome. Armonk, NY: Futura Publishing Co, 1999.
21. Bruns HJ, Eckardt L, Vahlhaus C et al. Body surface potential mapping in patients with Brugada syndrome: right precordial ST segment variations and reverse changes in left precordial leads. Cardiovasc Res 2002;54(1):58-66.
22. Shimizu W, Matsuo K, Takagi M et al. Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms. J Cardiovasc Electrophysiol 2000;11(4):396-404.
23. Oetgen WJ, Tibbits PA, Abt ME et al. Clinical and electrophysiologic assessment of oral flecainide acetate for recurrent ventricular tachycardia: evidence for exacerbation of electrical instability. Am J Cardiol 1983;52(7):746-50.
24. Echt DS, Black JN, Barbey JT et al. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs. Sodium channel block and action potential prolongation. Circulation 1989;79(5):1106-17.
25. Alings M, Wilde A. 'Brugada' syndrome: clinical data and suggested pathophysiological mechanism. Circulation 1999;99(5):666-73.
26. Eckardt L, Kirchhof P, Schulze-Bahr E et al. Electrophysiologic investigation in Brugada syndrome; yield of programmed ventricular stimulation at two ventricular sites with up to three premature beats. Eur Heart J 2002;23(17):1394-401.